Evidencias

Listado de publicaciones

• Miller et al 2019: Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors 
  https://www.frontiersin.org/articles/10.3389/fvets.2019.00106/full
   
• De Ridder et al 2020: Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
  https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.15806
   
• Campbell et al 2019: Durability of Clinical Response to intratumoral tigilanol tiglate in canine MCT
  https://qbiotics.com/pub/Durability_of_Clinical_Response_to_intratumoral_tigilanol_tiglate_in_canine_MCT-VCS_2019.pdf
   
• Melo et al 2019: Intra-tumoral injection of Tigilanol Tiglate in canine mast cell tumors: Time-assessed thermographic images, computed tomography and clinical response
  https://qbiotics.com/pub/Melo_S_Abstract_VCS2019.pdf
   
• Boyle et al 2014: Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108887
   
• Campbell et al 2017: Using triamcinolone in combination with the investigational anticancer agent EBC-46 (tigilanol tiglate) in the local treatment of a canine subcutaneous mast cell tumour
  https://qbiotics.com/pub/CandT_No_5598-final.pdf
   
• Panizza et al 2019: Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)
  https://www.sciencedirect.com/science/article/pii/S2352396419307868 
   
• Wiest et al 2019: Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors
  https://qbiotics.com/pub/ACVIM_2019_abstract_tiglanol_tiglate_pivotal_trial.pdf
   
• Reddel et al. 2020. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
  https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.16009
   
• Jones et Al. 2020. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate
  https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.16018
   
• Moses, Boyle, Howard-jones, Errington, Johns, Gordon, Reddell, Steadman, Moseley. Novel epoxy-tiglanes stimulate skin keratinocyte wound healing responses and re-epithelialization via protein kinase C activation. Biochemical Phamacology, 178 (2020) 114048.
  https://pubmed.ncbi.nlm.nih.gov/32446889/